Manuscript ID eji.201444651 entitled "Impaired dendritic cell IL-12 expression and distorted immunity against Leishmania infection in Batf3-deficient mice" which you submitted to the European Journal of Immunology has been reviewed.
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Major concerns:
1) The authors concluded that there is no defect in antigen presentation at the beginning of the infection.
However, what happens when the infection is established? The authors start to see differences in protection at week 1 (with high dose of parasites) or at week 2 (with low dose of parasites). Could you perform the antigen presentation assay at 1-2 weeks after infection when parasite load is detectable (so there is enough antigen in the skin and skin draining LN)?
2) The authors can detect skewing to Th2 and Treg responses early in the infection, but by 7 weeks it seems there is no difference between WT and Batf3-/-. This may be because in WT the infection is cleared by week 7. Thus, it would be informative to compare Th2 and Treg responses between Batf3-/mice and in Balb/c mice (known to generate a strong Th2 response).
3) Figure 3 is not clear and the explanation needs to be reformulated. (A) Gating strategy for monocytederived DCs and macrophages need to be shown in supplemental. As described recently by Malissen's & Henri's group (Immunity 2013), macrophages and monocyte-derived DCs have to be distinguished by the used of several markers (not only CD11b, Ly6C, and MHCII). These markers include CD64 and MerTK.
(B) IL-12 is a heterodimeric cytokine and both subunits have to be formed in the same cell to generate the biological active heterodimeric IL12p70. Consequently, RNA levels of IL12p40 are not sufficient to evaluate IL12. RNA levels of IL12p35 are necessary. Also, IL12 has to be measured at the protein level by ELISA. (C) It is not clear to me why the authors showed in Fig. 3B decrease in INOS by MFI, but then in Figure 3F they claimed that there is no difference in iNOS RNA. I think this has to be re-formulated, with special emphasis in why iNOS is playing (or not) a role in Batf3-/-mice.
Minor comments:
1) The authors need to introduce and discuss the work published by Hans Acha-Orbea group, and emphasize differences between both manuscripts.
2) The English has to be revised in the abstract, intro and conclusion
3) It is not clear why the authors used the 50,000-parasite dose to study immune response. Why the author said, "this dose is more appropriate for studying the generation of adaptive responses to the parasite". Please explain. with the expected reduced IL-12 production and a reduced monocyte-macrophage response.
1. The problem is that the article reproduces a small part of a recently published study in Eur. J. Immunol.
(which is cited and only partly discussed).
We understand the concern of the reviewer. Using a different L. major infection model we find exacerbated pathology and skewed immunity that concur with the study by Ashok et al. that was published while we were preparing our manuscript for submission. We wish to highlight that the data in our original submission were obtained independently and before publication of the Ashok study, which clearly contributes to the robustness of the results from both studies. The study from Acha-Orbea's group is, of course, cited (now also in the Introduction) and discussed and, by submitting our data to the same Journal and managing editor, we have been totally honest about this.
After an extensive revision of our work, we believe that our manuscript contains strong novel data that go beyond the recently published study. The experiments by Ashok et al. elegantly establish a role for "crosspresenting" DC (see title) in immunity against L. major infection, but do not allow the authors to clearly discern the mechanisms involved; whether it is cross-presentation or another function by these DCs, leaving many open questions. Moreover, local T cell response, which is key for our novel conclusions, was not investigated by Ashok et al. due to the different infection model used for analysis of immunity.
Additionally, there are two Batf3-dependent DC subsets that are differentially affected in the C57BL/6 background: -CD8α+ DC in the dLN, which we and others show are not affected in numbers (Supporting information, Fig. 1 and 2 ; references 11-13 in the manuscript) but are partially affected in function: e.g. Batf3-deficiency impairs cell-associated (but not soluble) antigen cross-presentation by this subset (see Fig. 3B in reference 12 in the manuscript).
-CD103+ dermal DCs that are found in the dLN as migratory DCs and are deficient in Batf3-/-mice in the C57BL/6 background both in the dLN (References 11, 12 and Supporting information, Fig. 1 and 2 ) and in the skin (as we first show here in the C57BL/6 background, Supporting information, Fig. 1 and 2 ).
Ashok et al. do not comprehensively address which Batf3-dependent DC subset is mediating immunity against L. major. In fact, they conclude that is mainly the CD8α+ DC subset, based on an experiment in which CD8α+ DC present antigen better than CD103+ DC ( Fig. 4 in their paper). We find that CD8α-CD103-cDCs are superior at L. major antigen presentation ex vivo ( Fig. 2C and D) and that the mechanism is not based on the different presentation ability, but rather on providing signal 3 (Fig. 5 ).
Our revised manuscript goes beyond the state of the art to establish that: 1) Batf3 deficiency leads not only to exacerbated pathology, but also to a lack of resolution with tissue loss ( Fig. 1A and Supporting information 1). The model used is more robust than the published one, with 1000fold differences in parasitemia detected ( Fig. 1B) .
2) By using i.d. infection, we can analyse local immune infiltrates ( Fig. 1C ) and show massive neutrophilia in lesions from Batf3-/-mice.
3) Batf3-deficiency does not affect early or late Leishmania antigen presentation to CD4+ and CD8+ T cells ( Fig. 2A and B ).
4)
We establish that CD8-CD103-DCs in the dLN are crucial for antigen presentation during L. major infection, whereas CD8+ cDC or migratory CD103+ DC in the dLN are not mediating antigen presentation to CD4+ and CD8+ T cells ( Fig. 2C and D) . 5) Ashok et al. find a moderate and transient decrease in IFN-γ levels in the dLN. In contrast, we do not find a significant reduction in IFN-γ in the dLN (Fig. 3A ). Our analysis of the local immune response reveals that the significant impairment in Th1 immunity is only found in effector CD4+ T cells in the skin ( Fig. 3B and C). Impairment in local Th1 immunity in Batf3-/-mice is comparable to that of Balb/c mice, whereas skewed immunity towards Th2 or Treg response is much less pronounced than in Balb/c mice (Supporting information Fig. 2 ). 6) We find a partial effect in monocyte differentiation in the dermis that we believe may be a consequence rather than a major driver of the phenotype (Fig. 4 and Supporting information Fig. 3 ).
5)
We describe that expression of IL-12p40 and IL-12p35 is impaired in CD11c+ cells from dLN and CD45+ cells from the skin in the absence of Batf3 ( Fig. 5A and B ). 6) By analysing cytokine production in DC subsets, we establish that Batf3-dependent CD103+ DCs both in dLN and dermis are crucial providers of IL-12 ( Fig. 5C-E ).
Peer review correspondence 7) Novel "rescue" experiments with WT and IL12p40-/-DC show that the sole transfer of these DCs drives IL-12-dependent elimination of the parasite (Fig. 5F ).
Consequently, our novel data support the notion that a subset of Batf3-dependent DC, CD103+ DC in dLN and dermis, are crucial for maintenance of local Th1 immunity by providing the crucial IL-12 "signal 3", rather than acting on antigen presentation, which is mediated by other DC subsets (namely CD8-cDC or monocyte-derived DC). In our opinion, this conclusion represents an important conceptual advance compared with the very recent study from Ashok et al.
2.
Another problem is the lack of a discussion and presentation of results on the role of other BatF transcription family members that allow CD8 and CD103 DC differentiation. At least the appearance of these subsets should be followed through the course of infection and it should be monitored for longer if the BatF3 KO mice heal the lesions later after infection.
As suggested by the reviewer, the appearance of CD8+ and CD103+ DC subsets has been analysed in the dLN (CD8+ cDC and CD103+ migratory DC) and the skin (dermal CD103+ DC) in the steady state 3. In the discussion they mention that IL-12 is required for priming and for the maintenance of protection.
They should at least discuss the results presented in the recently published Eur-J. Immunol. paper, where elimination of cross-presenting cells from day 19-21 was sufficient to confer the BatF3 phenotype.
As suggested by the reviewer, we discuss more extensively this point in the revised manuscript (Page 12, 3rd paragraph). Ashok et al. find that depletion of cross-presenting DCs between days 17 and 19 p.i. transiently enhances susceptibility to infection. Our results on the local impairment of Th1 immunity (which was not analysed in the report by Ashok et al.) would suggest that the critical role of CD103+ DC-derived IL-12 would be in the local maintenance of Th1 immunity rather than priming in the dLN, as stated above.
We find that the local response is important to control parasitemia starting between 2 and 3 weeks ( We hope that this concern has been addressed by the addition of new data in the revised manuscript, which allow us to propose and support novel concepts that go beyond the state of the art, as enumerated above.
Reviewer: 2
Comments to the Author
The study for Martina-Lopez et al address the contribution of skin BATF3 dependent CD103+ DCs to the response to L. major infection and show that absence of this cell type does not affect antigen presentation to antigen specific CD8 and CD4 cells, but rather results in less IL-12 secretion (which is expected from previous literature), and by consequence to less Th1 priming, distorted polarization, that likely results in delayed pathogen clearance and unresolved skin inflammation.
1. This study is of interest and straightforward. However, the authors should perform a "rescue" experiment by injecting CD103+ DCs in the infected ear of BATF3KO (probably at early stage) to test if the complementation with CD103+ DCs (only IL-12 secreting DCs…) will rescue their observed phenotype in absence of BATF3 dependent CD103+ DCs. This experiment (if successful) will also prove that no other cofounding effect associated with the use of a full KO model could indirectly explain their observations.
We thank the reviewer for the constructive criticism and suggesting the rescue experiment; the result of which supports a conceptual advance in the manuscript.
First, we established which DC subset is mainly responsible for IL-12 production in the L. major infection setting. The current literature is more focused on CD8α+ cDC and we find that, in fact, CD103+ DCs both in the dermis and the dLN are the main source of IL-12 during L. major infection ( Fig. 5C-E ).
We could not obtain CD103+ DCs ex vivo that were healthy enough to transfer to recipient mice, but we generated DC that are functionally equivalent by using Flt3L BMDC cultures treated with GM-CSF, as described (References 23, 24 in the manuscript). CD24hi DCs from these cultures were purified and Peer review correspondence transferred every 3 days, starting at day 4 p.i. We quantified parasitemia at 3 weeks, as the most relevant readout that correlates with pathology, and we found that transfer of Batf3-dependent DCs partially restores the response against the parasite (Fig. 5F ). Notably, transfer of IL-12p40-/-DCs did not rescue the phenotype, further supporting the notion that IL-12 produced by Batf3-dependent DCs is crucial for immunity against L. major.
2. The authors should also investigate and discuss more clearly why in another study, priming of L. majorspecific CD8+ T cells is reduced following depletion of Langerin+ dDCs? Is it because they are using a full KO mouse model while the other study used a model allowing the unique depletion of the langerin+ dDCs (= CD103+ DCs) at the time of the challenge? The discussion in the manuscript does not really provide any satisfying argumentation.
We could not find a reduction in CD8+ T cell priming in Batf3-/-mice early after infection with L. major ( Fig. 2A and B ). However, these results do not imply that langerin+ dDCs cannot prime CD8+ T cell responses during L. major infection, as described. This is now discussed more extensively (Page 11, 2nd paragraph) by arguing that Batf3-/-mice in the C57BL/6 background have normal numbers of CD8α+ cDC in the dLN and only partial depletion of CD103+ DC in skin or dLN ( Supplementary Figures 1 and 2) . The remaining DCs could be mediating normal priming of CD8+ T cells, as we find in our study.
In addition, our novel results show that CD8-CD103-DCs are the main subset responsible for antigen presentation in the dLN, 2 weeks p.i. (Fig. 2C and D) . A possible explanation for the Brewig et al. data is that rather than directly presenting the antigen, Langerin+ dDCs provide the antigen to other subsets that in turn presents it in the dLN.
Regardless, our results show that CD4+ or CD8+ T cell priming is not the crucial step affected by Batf3 deficiency, and is not the explanation for the impaired immunity against the parasite 3. Finally, although not affected in numbers, do monocyte-derived DCs secrete IL-12?
We show (Supporting information Fig. 3A ) that dermal monocyte-derived DCs produce IL-12 following L. major infection, as previously reported (Reference 5 in the manuscript). Batf3 deficiency partially affects not only monocyte differentiation but also IL-12 production by monocyte-derived DCs. However, partial deficiency in IL-12 producing monocyte-derived DCs is compensated by increased infiltrates in the lesions of Batf3-/-mice and the total numbers are not affected. Consequently, the global deficiency observed at the mRNA level ( Fig. 5A and B ) must be as a result of another DC subset, and we identify CD103+ DCs as the major IL-12 producer under L. major infection (Fig. 5C-E) .
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The partial effect on differentiation or functionality could be a consequence of skewed immunity, rather than the cause, as IL-12 and Th1 immunity contributes to the activation of monocyte-derived DCs, and a Th2 environment prevents local differentiation and functionality of monocyte-derived DCs (Reference 21 in the manuscript).
Reviewer: 3
Comments to the Author Martinez-Lopez and collaborators investigated the role of Batf-3-dependent DCs in the generation of immunity against L. major. They used a Th1-mediated self-healing model of infection, the C57BL/6 mouse.
The authors showed nicely that Batf3 deficiency results in exaggerated parasite load and unresolved pathology. Hans Acha-Orbea group has very recently published this result (EJI 2014). Thus, I think the authors need to emphasize the novelty of their work compared with that of Hans Acha-Orbea. This has to be done in the introduction and the conclusion of the manuscript.
We thank the reviewer for the constructive criticisms, which have allowed us to clarify and improve our manuscript, contributing to a conceptual advance. As suggested by the reviewer, we have now discussed the novelty of our work compared to the results of Hans Acha-Orbea's group, both in the introduction and discussion.
Our revised manuscript goes beyond the state of the art to establish that: 1) Batf3 deficiency leads not only to exacerbated pathology, but also to a lack of resolution with tissue loss ( Fig. 1A and supporting information 1) . The model used is more robust than the published one, with 1000fold differences in parasitemia detected (Fig. 1B) .
2) By using i.d. infection we can analyse local immune infiltrates (Fig. 1C ) and show massive neutrophilia in lesions from Batf3-/-mice.
3) Batf3-deficiency does not affect early or late Leishmania antigen presentation to CD4+ and CD8+ T cells ( Fig. 2A and B) .
4)
We establish that CD8-CD103-DCs in the dLN are crucial for antigen presentation during L. major infection, whereas CD8+ cDC or migratory CD103+ DC in the dLN are not mediating antigen presentation to CD4+ and CD8+ T cells ( Fig. 2C and D) .
Peer review correspondence
5) Ashok et al. find a moderate and transient decrease in IFN-γ levels in the dLN. In contrast, we do not find a significant reduction in IFN-γ in the dLN (Fig. 3A) . Our analysis of the local immune response reveals that the significant impairment in Th1 immunity is only found in effector CD4+ T cells in the skin ( Fig. 3B and C) . Impairment in local Th1 immunity in Batf3-/-mice is comparable to that of Balb/c mice, whereas skewed immunity towards Th2 or Treg response is much less pronounced than in Balb/c mice (Supporting information Fig. 2 ).
6)
We find a partial effect in monocyte differentiation in the dermis that we believe may be a consequence rather than a major driver of the phenotype (Fig. 4 and supporting information Fig. 3 ).
5)
We describe that expression of IL-12p40 and IL-12p35 is impaired in CD11c+ cells from dLN and CD45+ cells from the skin in the absence of Batf3 ( Fig. 5A and B ). 6) By analysing cytokine production in DC subsets, we establish that Batf3-dependent CD103+ DCs both in dLN and dermis are crucial providers of IL-12 ( Fig. 5C-E) . 7) Novel "rescue" experiments with WT and IL12p40-/-DC show that the sole transfer of these DCs drives IL-12-dependent elimination of the parasite (Fig. 5F ).
Also, I have outlined below several points that will enrich this manuscript and hopefully add new information to the field.
Major concerns:
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To address this question from the reviewer, we extracted DC from the dLN of L. major infected mice 2 weeks p.i. and co-cultured with CD4+ ( Fig. 2C) and CD8+ (Fig. 2D ) polyclonal T cells coming from L. major-healed mice. This antigen presentation assay showed that 2 weeks p.i., CD8α-CD103-DC in the dLN (which are Batf3-independent) are the major DC subset presenting L. major-derived antigens both to CD4+ and CD8+ T cells. These results support the concept that Batf3-dependent DC are mediating signal 3, rather than signals 1&2.
We agree with the reviewer that the peak in the difference is reached by 2-3 weeks p.i., with a decline in the WT response as infection is cleared. As requested, we have compared C57BL/6 WT, C57BL/6 Batf3-/and BALB/c WT mice for IFN-γ and IL-4 production in the dLN (Supporting information, Fig. 2A ) and for frequency of T cells producing IFN-γ or IL-4 or frequency of CD25+ FoxP3+ T cells locally in the ear (Supporting information, Fig. 2B and C) at the peak of the response, 3 weeks p.i. In this independent collection of experiments, we confirm a very significant decrease in local Th1 response in Batf3-/-mice compared with WT mice, comparable in magnitude to the still more significant reduction in local Th1 response in BALB/c mice (Supporting information Fig. 2B ). However, BALB/c mice have exacerbated Th2 and Treg responses compared with those of Batf3-/-mice (Supporting information, Fig. 2A-C) .
In conclusion, the suggestion of the reviewer has been valuable to discern that the key and most significant difference in the skewing of immunity in Batf3-/-mice compared with WT mice is the reduction in the Th1 local effector response. The effects in Th2 and Treg skewing in Batf3-/-mice are paltry in comparison with those in BALB/c mice.
3) Figure 3 is not clear and the explanation needs to be reformulated.
(A) Gating strategy for monocyte-derived DCs and macrophages need to be shown in supplemental. As As suggested, we have followed the quoted gating strategy to precisely quantify subsets of macrophages and monocyte-derived DCs. The analysis of subsets confirms an increase in dermal monocytes (P1) with some slight deficiency in differentiation of monocyte-derived DCs (P2 and P3) and dermal class II high Peer review correspondence macrophages (P5) in the absence of Batf3 (Fig. 4) . This partial deficiency in differentiation affects the frequency of cells, but the concomitant changes in inflammatory infiltrates result in negligible difference in absolute numbers except for slight increase in dermal monocytes (P1) and a decrease in dermal class II high macrophages (P5) by week 3 p.i.
(B) IL-12 is a heterodimeric cytokine and both subunits have to be formed in the same cell to generate the biological active heterodimeric IL12p70. Consequently, RNA levels of IL12p40 are not sufficient to evaluate IL12. RNA levels of IL12p35 are necessary. Also, IL12 has to be measured at the protein level by ELISA.
The reviewer is quite right. We have now analysed IL-12p35 mRNA expression ( Fig. 5A and B ). We have also evaluated an increased number of independent experiments, each with several biological replicates, to statistically analyse these results; subsequently, we demonstrate that Batf3 deficiency results in the significant reduction of IL-12p40 and IL-12p35 expression in DCs in the dLN (Fig. 5A ) and in CD45+ cells in the ear (Fig. 5B) .
Further, as suggested, we have measured IL-12p40 protein. ELISA would not allow us to discriminate the cell-type origin of IL12, which is one of the crucial questions that we wanted to address. Thus, we performed intracellular staining and found that CD103+ DCs are main producers of IL-12p40, both in the dLN and the dermis (Fig. 5C-E ).
(C) It is not clear to me why the authors showed in Fig. 3B decrease in INOS by MFI, but then in Figure 3F they claimed that there is no difference in iNOS RNA. I think this has to be re-formulated, with special emphasis in why iNOS is playing (or not) a role in Batf3-/-mice.
We apologize for the lack of clarity here, and agree that the results were not well explained, and probably distract from the main message of the study. They have now been placed in Supporting information, Fig.   3 .
In the original manuscript, we showed that although Batf3-dependent DCs may affect iNOS production by monocyte-derived DCs and macrophages, when the mRNA was analysed globally in the whole CD11c subset (dLN) or CD45+ cells in the ear, the difference was not significant. We think that increased infiltrates in Batf3-/-compensate for the cell-deficiency, as shown for deficient differentiation or IL-12 production in a cell-basis, but not in global numbers (Fig. 4 or Supporting information Fig. 3 ). Now, we normalize to β-actin and do not show these data, to avoid confusion.
We find a moderate but significant reduction in iNOS production (per cell) from the indicated subsets of dermal myeloid cells (Supplementary Figure 5B) . We believe that reduced local Th1 immunity could Peer review correspondence impact in the generation of iNOS by these subsets, as reported. It could also be related with the slightly reduced differentiation to MHC-class II high macrophages or DCs observed (Fig. 4) . But the global impact is probably limited by the increase in infiltrates in Batf3-/-mice.
As suggested by the reviewer, we have now introduced and discussed the work published by Hans Acha-Orbea's group and emphasise the novelty of our work, as explained above.
The previous version of the manuscript was carefully checked by our Scientific Editor, as indicated in Acknowledgements. In this version of the manuscript, we have revised the style and syntax and it has been re-edited by our Scientific Editing facility.
3) It is not clear why the authors used the 50,000-parasite dose to study immune response. Why the author said, "this dose is more appropriate for studying the generation of adaptive responses to the parasite". Please explain.
While the use of injection of 1000 parasites is closer to the real infection setting, which was used for the initial pathology studies (Fig. 1A , Supporting information Fig. 1A and B ), we find induction of more robust adaptive responses at an earlier time point with 50,000 parasites. This is still a low amount of parasite, compared to the 3x106 parasites that are used for analysis of adaptive responses in the footpad model in the related paper by Ashok et al. However, we agree that 1000 parasites could have been even more appropriate, as closer to the real infection, and we have removed the sentence. You should also pay close attention to the editorial comments included below.
If the revision of the paper is expected to take more than three months, please inform the editorial office.
Revisions taking longer than six months may be assessed by new referee(s) to ensure the relevance and timeliness of the data.
Once again, thank you for submitting your manuscript to European Journal of Immunology. We look forward to receiving your revision. Comments to the Author I read with interest the new paper that has been completely rewritten with new results added. It is much better now and has some new results that merit publication. There are, however, some important remaining questions.
1) In the published article by Ashok et al., the authors already showed that the BatF3 KO mice are much more susceptible to the low dose ear infection. One of the key points of the article is that after high-dose subcutaneous Leishmania injection, from day 19-21 cross-presenting DC are required to induce an IL-12mediated protection by triggering an IL-12 response. Also CD8 DC but not CD103 DC ex vivo at 3 weeks post infection did present Leishmania antigens ex vivo, contrary to this study where both subsets, 2 weeks after the lower dose ear infection model did not show any restimulation capacity. It would be important to show whether one of the 2 subsets is able to present antigens ex vivo at later time points, especially in their lower dose infection model.
2) CD8 is a useful marker for DC subsets but other subsets might upregulate this marker after activation.
Maybe it would be worth using CD8 in combination with CD24 to exclude dilution of the CD8 subset with other activated subsets.
3)Is the CD103 DC subset present (at which percentage) in the Flt-3, GM-CSF-derived bone marrow-DC used for adoptive transfer? This is really important to support the presented data and interpretation as the article does not show directly that the CD103 cells are involved in the Th1 induction and this is in conflict with the Ashok paper.
Reviewer: 2
Comments to the Author The authors addressed all my concerns and significantly improved their study. Well done.
Reviewer: 3
Comments to the Author The authors have answered all my questions and concerns. This paper has improved in quality and significance after revision.
Second Revision -authors' response -24 August 2014
Reviewer: 1Comments to the AuthorI read with interest the new paper that has been completely rewritten with new results added. It is much better now and has some new results that merit publication.
Thank you for the constructive criticisms, which have helped us to improve the manuscript, and for being open about the progress of our new results beyond the state of the art.
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There are, however, some important remaining questions. 1) In the published article by Ashok et al., the authors already showed that the BatF3 KO mice are much more susceptible to the low dose ear infection. One of the key points of the article is that after high-dose subcutaneous Leishmania injection, from day 19-21 cross-presenting DC are required to induce an IL-12mediated protection by triggering an IL-12 response. Also CD8 DC but not CD103 DC ex vivo at 3 weeks post infection did present Leishmania antigens ex vivo, contrary to this study where both subsets, 2 weeks after the lower dose ear infection model did not show any restimulation capacity. It would be important to show whether one of the 2 subsets is able to present antigens ex vivo at later time points, especially in their lower dose infection model.
We do not find any evidence in the paper by Ashok et al. demonstrating that "cross-presenting DC are required to induce an IL-12-mediated protection by triggering an IL-12 response". The paper nicely shows that immunity to the parasite cannot be achieved either in the absence of cross-presenting DC or even through systemic IL-12 blockade ( Figure 5I ), but the connection that IL-12 is coming from DC is not established. We go further in showing this connection and that CD103+ DC are a major source of IL-12 during L. major infection selectively affected in numbers and function by Batf3 absence.
The reviewer also indicates an apparent controversy between our data and those of Ashok et al. and we believe that this point needs further clarification. Regarding the new experiment proposed by the reviewer, we do not think that analysing ex vivo antigen presentation at 3 weeks or later would show much of a difference from our analysis at 2 weeks p.i. In fact, we do not see major discrepancies between our study and that of Ashok et al. We also find some presentation to CD4+ T cells of Leishmania antigens by CD8α+ cDC or CD103+ mDC extracted ex vivo following L. major infection ( Figure 2C and D), but this poor stimulation is overshadowed by the antigen presentation by CD8α-cDC. When Ashok et al. took the DC ex vivo from infected mice (DC + T, in their Figure 4B ); the capacity to present antigen and induce an IFNγ response is probably comparable to what we see ( Figure 2C ), but they did not compare with Batf3independent CD8α-cDC. The main role of CD8α-cDC in L. major antigen presentation concurs with references 6 and 7 in our manuscript.
As this is an important point in which our manuscript goes beyond the paper by Ashok et al., we have now extended the discussion of this issue (page 11, 2nd paragraph).
Our data support the main message from Ashok et al. on the crucial role of Batf3-dependent DCs in priming anti-Leishmania response, but explore the mechanisms further by clarifying that they provide the essential signal 3, rather than acting at the level of antigen presentation. And we show that the Batf3dependent CD103+ DC excel at IL-12 production during L. major infection.
